CN110616192B - 一种抗人神经丝轻链(nefl)的单克隆抗体及其应用 - Google Patents

一种抗人神经丝轻链(nefl)的单克隆抗体及其应用 Download PDF

Info

Publication number
CN110616192B
CN110616192B CN201910732612.2A CN201910732612A CN110616192B CN 110616192 B CN110616192 B CN 110616192B CN 201910732612 A CN201910732612 A CN 201910732612A CN 110616192 B CN110616192 B CN 110616192B
Authority
CN
China
Prior art keywords
antibody
nefl
oti11f6
monoclonal antibody
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910732612.2A
Other languages
English (en)
Other versions
CN110616192A (zh
Inventor
唐雨德
付伟
扈晓敏
任琪
钮倩
王成林
沈腾腾
何为无
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WUXI ORIGENE BIO-TECHNOLOGY CO LTD
Original Assignee
WUXI ORIGENE BIO-TECHNOLOGY CO LTD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WUXI ORIGENE BIO-TECHNOLOGY CO LTD filed Critical WUXI ORIGENE BIO-TECHNOLOGY CO LTD
Priority to CN201910732612.2A priority Critical patent/CN110616192B/zh
Publication of CN110616192A publication Critical patent/CN110616192A/zh
Application granted granted Critical
Publication of CN110616192B publication Critical patent/CN110616192B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明涉及生物技术领域,公开了一种抗神经丝轻链(NEFL)的单克隆抗体,所述的抗体是由保藏号为CGMCC No.18189的杂交瘤细胞株OTI11F6分泌产生。所述抗体的免疫原是原核细胞表达的NEFL 1‑360aa多肽。所述抗体的轻链(VL)的氨基酸序列如SEQ ID NO.1所示,其重链(VH)的氨基酸序列如SEQ ID No.2所示。所述抗体的VL包括3个抗原决定簇:CDR1、CDR2和CDR3,其氨基酸序列分别如SEQ ID No.3‑5所示,所述抗体的VH区域包括3个抗原决定簇:CDR1、CDR2和CDR3,其氨基酸序列分别如SEQ ID No.6‑8所示。所述抗体OTI11F6可应用于人NEFL的各种免疫检测试剂盒的制备,包括双抗体夹心酶联免疫试剂盒或化学发光法试剂盒的制备,为临床上对脑损伤与脑慢性病变提供辅助诊断。

Description

一种抗人神经丝轻链(NEFL)的单克隆抗体及其应用
技术领域
本发明属于生物技术领域,涉及一种抗人NEFL的单克隆抗体及其在免疫检测方面的应用。
背景技术
神经中间丝或称神经纤维丝包括3个亚基:神经丝轻链(neurofilament lightpolypeptide,NEFL)、神经丝中链(NEFM)和神经丝重链(NEFH),相对分子质量分别为68,000、160,000和212,000。NEFL是唯一可以自我组装的亚单位,NEFL在体外可自我组装成同型多聚体的10nm的纤维,当NEFL亚单位缺少时,神经丝中链多肽和神经丝重链多肽亚单位不能组装成功能性神经丝蛋白,因而NEFL被认为是最重要的神经纤维丝。
NEFL是组成神经细胞骨架的关键成分,并与对神经细胞塑形至关重要的多个蛋白靶点有相互联系,在维持神经细胞形态及使有髓鞘的轴突再生方面起关键性作用。近年来发现,NEFL与神经系统相关疾病的关系密切,是阿尔茨海默病、脑震荡、帕金森氏综合征等脑部病变的血液生物标志物,也发现NEFL可能与神经系统以外肿瘤的发生、发展密切相关,如乳腺癌、肺癌、头颈部肿瘤等。因此,采用具有高灵敏度和高特异性的检测NEFL方法在相关人群中进行筛查,对相关疾病的诊断具有重大意义。
NEFL共543aa,含2个糖基化位点,2-543aa为主链。其中2-92aa为链的头部,是抗体结合区;93-396aa是链体,其特别的质量和高电荷密度有别于其他神经丝蛋白但与其他神经丝的同源性非常高;397-543aa是链的尾部,影响链的空间结构。NEFL的含量在脑脊液中远高于血液,两者相差近10倍,因此,寻找高特异性和高敏感性的抗NEFL抗体是建立检测血液NEFL方法的关键。检索中国、美国、EPO、WIPO等专利网站,利用neurofilament light或NEFL+monoclonal antibody或antibody作为关键词,有关与NEFL具有高亲和力和特异性结合的单克隆抗体的专利没有查到,有关检测利用抗NEFL鼠单克隆抗体OTI11F6制备免疫检测试剂盒也未查到;利用neurofilament light或NEFL+monoclonal antibody或antibody作为关键词,在pubmed仅查到一篇文献即Anovel duplication/insertion mutationofNEFL in a patient with Charcot-Marie-Tooth disease,相关内容与本发明无关。查询中国市场监督管理总局(原国家药品监督管理局)网站,还没有与NEFL相关的检测试剂注册。
发明内容
本发明的目的是提供一种特异性好、亲和力高的抗NEFL单克隆抗体及其在双抗体夹心酶联免疫法或板式化学发光法制备的免疫检测试剂盒中的应用,为与NEFL相关的疾病提供辅助诊断,也为下一步工程抗体的制备提供基础。
所述的抗NEFL单克隆抗体OTI11F6,是由保藏号为:CGMCC No.18189的杂交瘤细胞株OTI11F6分泌产生。
所述的杂交瘤细胞株OTI11F6是以原核细胞表达的NEFL 1-360aa为免疫源,通过免疫注射小鼠,取免疫小鼠脾脏制备悬液,并使之与骨髓瘤细胞进行细胞融合获得。
所述的单克隆抗体OTI11F6,其轻链的氨基酸序列如SEQ ID NO.1所示,其重链的氨基酸残基序列如SEQ ID NO.2所示。
所述的抗体OTI11F6,其VL区域包括3个抗原决定簇:CDR1、CDR2和CDR3,抗原决定簇的区域相应地分别为27aa-38aa,56aa-58aa和95aa-101aa。其氨基酸序列分别:QSLLYSGNQKNY、LAS、TYIVPYT。
所述的抗体OTI11F6,其VH区域包括3个抗原决定簇:CDR1、CDR2和CDR3,抗原决定簇的区域相应地分别为26aa-33aa,51aa-60aa和99aa-110aa。其氨基酸序列分别为GFTFTDFY、SKVKAFGYTT、ALGRGWYFDVVK。
所述的抗体OTI11F6可以与NEFL高特异性结合,可通过本领域技术人员所公知的的方法,制备成检测NEFL的各种免疫检测试剂盒,尤其是,应用于化学发光法制备的免疫检测试剂盒中。板式化学发光法检测NEFL标准品,检测灵敏度能达到1.6pg/ml,线性范围为1.6-1000pg/ml,剂量-反应曲线的线性R2值为0.9623;检测临床血液样品,板式化学发光法检测NEFL灵敏度能达到4.96pg/ml。
保藏信息
用于保藏的杂交瘤细胞株OTI11F6的分类命名为:鼠抗人神经丝轻链(NEFL)单克隆杂交瘤细胞株;
保藏单位全称:中国微生物菌种保藏管理委员会普通微生物中心;
保藏单位简称:CGMCC;
保藏单位地址:北京市朝阳区北辰西路1号院3号中国科学院微生物研究所;
保藏日期:2019年7月11日;
保藏编号:CGMCC No.18189。
附图说明
图1为5’RACE产物电泳图,从左到右,分别为DNAMarker、轻链结果和重链结果。
图2为板式化学发光免疫检测NEFL的标准曲线,R2值为0.9623。根据信噪比大于2.0判定,本发明所述的OTI11F6单克隆抗体用于板式化学发光免疫检测试剂,最低灵敏度大于1.6pg/ml,线性范围为1.6-1000pg/ml。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件、实验室手册中所述的条件或按照制造厂商所建议的条件。
实施例1:抗NEFL单克隆抗体的制备
一、NEFL重组蛋白的生产
从Genebank中选调NEFL基因NM_006158,该基因编码NEFL全长543个氨基酸(aa),位于355-1986nt,本发明所述抗体的免疫原为NEFL1-360aa,位于第355-1432nt,采用本领域技术人员所知的技术方法将该基因克隆到pET23a表达质粒中,C端带his tag,在BL21大肠杆菌中表达,镍柱纯化,SDS-PAGE电泳鉴定纯度。电泳后从凝胶上观察到分子量为43kDa左右的目的蛋白条带,纯度在90%以上,达到了制备单抗的纯度要求。
二、动物免疫
上述纯化的NEFL重组蛋白以完全弗氏佐剂乳化,采用皮下或腹腔注射方法免疫6-8周龄BALB/c小鼠,免疫剂量为80μg/只,间隔两周后进行第二次免疫,以不完全弗氏佐剂乳化,免疫剂量为60μg/只。免疫两次后取尾血以ELISA法梯度稀释测定血清效价;根据检测的效价结果确定是否加强免疫,选取抗体效价最高的小鼠进行细胞融合。
三、细胞融合、克隆筛选取免疫小鼠脾细胞与小鼠骨髓瘤细胞SP2/0融合,脾细胞与SP2/0细胞以10:1混合,以50%PEG4,000介导融合,离心后重悬于HAT选择性培养基中,接种于含有饲养细胞的96孔微孔板中,置37℃、5%CO2培养箱培养,融合后第4d、第7d用HAT培养液半量换液,10d后换用HT培养液。观察杂交瘤细胞的生长情况,等克隆长至孔底面积的1/4~1/3,取培养上清液,用ELISA法进行抗体检测,筛选阳性克隆孔。以有限稀释法对阳性孔的杂交瘤细胞进行克隆化培养,直到克隆化细胞抗体阳性率为100%,选岀高分泌特异性细胞株(即ELISA效价在1:104以上的阳性克隆),此时可将阳性克隆细胞进一步扩大培养,直至细胞系能稳定分泌单克隆抗体。
四、单克隆抗体的制备和纯化以无血清培养基悬浮培养杂交瘤细胞,1周左右当细胞上清体积扩培到任务量及细胞死亡率达到60%-70%时,收取细胞悬液,离心取上清,亲和层析法进行抗体纯化,根据抗体亚型选择相应柱料进行纯化。以BCA法测定纯化后的单抗浓度,再分装、冻存。
实施例2:抗NEFL单克隆抗体的鉴定
通过实施例1获单克隆抗体4株,分别为OTI3G2、OTI11F6、OTI2F5、OTI11F8,分别做如下鉴定。
一、单克隆抗体的特异性鉴定
采用间接ELISA法检测。以NEFL、NEFM、NEFH、GFAP、UCH-L1、BSA、PET23a空质粒转大肠杆菌的裂解液、PCMV6质粒转293细胞裂解液等蛋白包被酶标板,浓度为5μg/ml,4℃过夜,以含1%BSA的PBST封闭酶标板,加104倍稀释的纯化抗体,37℃反应50min,PBST洗板3次,加HRP标记的羊抗鼠二抗。
结果显示,NEFM、NEFH、GFAP、UCH-L1、BSA、PET23a空质粒转大肠杆菌的裂解液、PCMV6质粒转293细胞裂解液与4株抗体反应均为阴性,OD450均在0.1以下;NEFL与4株抗体反应均阳性,OD450均在1.5以上,说明实施例1获得的抗NEFL单克隆抗体对NEFL具有高度特异性。
二、单克隆抗体的效价与亚型
采用商品试剂盒,检测纯化前细胞培养上清,测IgG亚型;以倍比稀释法稀释纯化的抗体,用间接ELISA测抗体效价,从表1可知本发明涉及的抗体OTI11F6的ELISA效价为1.024×106,亚型为IgG1型。根据间接ELISA法效价,计算OTI11F6单克隆抗体的亲和常数Ka=1.4×109L/mol,属于高亲和力抗体。
表1.抗NEFL单克隆抗体的效价与亚型
抗体效价 IgG亚型
OTI11F8 5.12×10<sup>5</sup> IgG1
OTI2F5 1.024×10<sup>6</sup> IgG1
OTI3G2 5.12×10<sup>5</sup> IgG1
OTI11F6 1.024×10<sup>6</sup> IgG1
三、抗体配对
为了挑选包被抗体和检测抗体的最佳组合,采用棋盘组合,将OTI3G2、OTI11F5、OTI11F6和OTI11F84株单克隆抗体分别包被酶标板,4℃过夜。第二天取出酶标板,PBST洗涤一次,1%BSA溶液37℃封闭2小时,PBST洗涤3次;每孔加入NEFL真核重组抗原100μl,浓度分别为500、50、5和0ng/ml,37℃孵育1小时;孵育完成后取出酶标板,PBST洗涤3次,分别加入HRP标记的上述4株抗体作为检测抗体,将4株单克隆抗体和所对应的酶标单抗两两配对进行双抗体夹心ELISA实验,37℃孵育1小时。PBST洗涤5次,加入TMB底物,37℃显色10min。取出后加终止液,在酶标仪上测定OD450读数。根据样品的OD值与阴性对照的背景值,选出最为理想的单克隆抗体对,配对筛选结果见表2。从表2可知,本发明权利要求2所述的抗体OTI11F6无论是做包被抗体还是检测抗体,都可以与OTI3G2进行配对,但作为检测抗体的结果最佳。
表2.抗体配对实验筛选结果
Figure GDA0003150023760000051
Figure GDA0003150023760000061
实施例3:单克隆抗体的可变区的基因测序与分析
从Takara Bio USA公司采购
Figure GDA0003150023760000062
RACE 5’/3’试剂盒,采用5’RACE(RapidAmplification ofcDNA Ends,快速扩增cDNA末端)技术从分泌抗NEFL单克隆抗体的杂交瘤细胞株OTI11F6中克隆功能性抗体的可变区序列。具体实验过程如下参见Takara Bio USA公司
Figure GDA0003150023760000063
RACE 5’/3’Kit使用者手册。
根据所述的抗体OTI11F6为IgG1亚型,设计针对其Ig和Kapa恒定区3’端的特异性基因引物pRace-H-GSP和pRace-K-GSP,引物序列如下:
pRace-H-GSP:CATCDGTCTATCCACTGGCCCCTG
pRace-K-GSP:CTTCCCACCATCCAGTGAGCAGTT
经RACE PCR扩增获得抗体轻链和重链的DNA片段,结果见图1,从图1可知,扩增的抗体轻链和重链的DNA片段大小在500bp左右,与鼠抗体可变区基因相符。将RACE扩增产物分别连于克隆载体PUC119,通过蓝白斑挑取阳性克隆进行测序,测序仪为ABI 3730,测序引物为通用引物M13f和M13r。经测序软件拼接,获得单克隆抗体OTI11F6的轻链可变区和重链可变区的核苷酸序列。
利用互联网,在http://www.imgt.org上使用IMGT/V-QUEST分析软件进行测序结果数据分析,得到抗体序列的轻链链氨基酸序列如SEQ ID NO.1所示,重链氨基酸序列如SEQ ID NO.2所示。VL全长为112个氨基酸,其FR的4个结构域氨基酸数分别为26、17、36和11,CDR的3个结构域氨基酸数分别为12、3和7,CDR1、CDR2和CDR3的区域相应地分别为27aa-38aa,56aa-58aa和95aa-101aa,其氨基酸序列分别:QSLLYSGNQKNY、LAS、TYIVPYT。VH全长为121个氨基酸,其FR的4个结构域氨基酸数分别为25、17、38和11,CDR的3个结构域氨基酸数分别为8、10和12,CDR1、CDR2和CDR3分别为26aa-33aa,51aa-60aa和99aa-110aa,其氨基酸残基序列分别为GFTFTDFY、SKVKAFGYTT、ALGRGWYFDVVK。这些结构均符合鼠抗体特征。
实施例4:本发明的抗NEFL单克隆抗体的应用
采用本领域技术人员所公知的基于双抗体夹心法原理的板式化学发光免疫检测技术,制作NEFL检测试剂盒,在体外定量检测人血清中的NEFL的含量,用于临床上与NEFL相关疾病辅助诊断。
一、检测原理与方法
采用基于双抗体夹心法原理的板式化学发光免疫检测技术。在不透光的白色微孔板内包被抗NEFL的单克隆抗体OTI3G2,将标准品或待测标本加入微孔中进行温育,在温育过程中,标本中的NEFL与单克隆抗体结合形成复合物。洗涤除掉未结合的物质,再加入辣根过氧化物酶(HRP)标记的单克隆抗体OTI11F6进行温育,则酶标记单克隆抗体与微孔内的复合物形成抗体-抗原-抗体复合物。洗涤除去未结合的物质,加Thermo ScientificSuperSignal ELISA Pico化学发光底物,HARTA MicroLumi L2发光仪读数,依据信噪比大于2.0判读结果为阳性。发光值的大小反映了结合的酶标抗体的量,它与标本中的NEFL的浓度成正比。根据所测定的标准品的发光值绘制标准曲线,待测标本中的NEFL浓度值即可从标准曲线上获得。
二、对真核重组抗原的检测与标准曲线制作
把真核细胞293T表达的NEFL抗原进行梯度稀释,分别为0pg/ml、0.8pg/ml、1.6pg/ml、8pg/ml、40pg/ml、200pg/ml、1000pg/ml,以OTI3G2抗体为包被抗体、本发明所述的OTI11F6抗体为检测抗体,用上述检测方法检测7个梯度稀释的抗原,检测结果见表3。以抗原浓度为横坐标、发光值为纵坐标,依据表3制作NEFL检测标准曲线,见图2,R2值为0.9623。根据信噪比大于2.0判定,本发明所述的OTI11F6单克隆抗体用于板式化学发光免疫检测试剂,最低灵敏度大于1.6pg/ml,线性范围为1.6-1000pg/ml。
表3.板式化学发光法检测NEFL真核重组抗原
Figure GDA0003150023760000071
三、样本检测
用上述方法检测15例60岁心血管疾病病人血清,依据发光值查标准曲线,得出对应的NEFL浓度,结果见表4。根据信噪比,本发明所述的OTI11F6抗体为检测抗体用于板式化学发光免疫检测,血清NEFL的最低检测值是4.96pg/ml,为与NEFL相关的疾病诊断提供辅助手段。
表4.病人血清中NEFL的检测
Figure GDA0003150023760000081
序列表
<110> 无锡傲锐东源生物科技有限公司
<120> 一种抗人神经丝轻链(NEFL)的单克隆抗体及其应用
<140> 2019107326122
<141> 2019-08-09
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 112
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 1
Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly
1 5 10 15
Glu Lys Val Thr Val Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Ser Pro Lys Leu Leu Ile Tyr Leu Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Thr Tyr
85 90 95
Ile Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
100 105 110
<210> 2
<211> 121
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 2
Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Thr Asp Phe
20 25 30
Tyr Met Asn Trp Val Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Phe Ser Lys Val Lys Ala Phe Gly Tyr Thr Thr Glu Asn Asn Ala
50 55 60
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Gly Phe
65 70 75 80
Leu Tyr Leu Gln Met Asn Thr Leu Ser Pro Glu Asp Ser Ala Thr Tyr
85 90 95
Tyr Cys Ala Leu Gly Arg Gly Trp Tyr Phe Asp Val Val Lys Trp Gly
100 105 110
Ala Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 3
<211> 12
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 3
Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr
1 5 10
<210> 4
<211> 3
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 4
Leu Ala Ser
1
<210> 5
<211> 7
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 5
Thr Tyr Ile Val Pro Tyr Thr
1 5
<210> 6
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 6
Gly Phe Thr Phe Thr Asp Phe Tyr
1 5
<210> 7
<211> 10
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 7
Ser Lys Val Lys Ala Phe Gly Tyr Thr Thr
1 5 10
<210> 8
<211> 12
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 8
Ala Leu Gly Arg Gly Trp Tyr Phe Asp Val Val Lys
1 5 10

Claims (3)

1.一株分泌抗人神经丝轻链(NEFL)蛋白的单克隆抗体的杂交瘤细胞株OTI11F6,于2019年7月11日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCCNo.18189。
2.由权利要求1所述的杂交瘤细胞株OTI 11F6分泌的抗人NEFL蛋白单克隆抗体OTI11F6,其特征在于:其轻链可变区(VL)的氨基酸序列如SEQ ID NO.1所示;其重链可变区(VH)的氨基酸序列如SEQ ID NO.2所示。
3.一种权利要求2所述的抗人神经丝轻链(NEFL)蛋白单克隆抗体OTI11F6的应用,其特征在于:用于人NEFL免疫检测试剂盒的制备,包括但不限于双抗体夹心ELISA检测试剂盒和化学发光免疫检测试剂盒。
CN201910732612.2A 2019-08-09 2019-08-09 一种抗人神经丝轻链(nefl)的单克隆抗体及其应用 Active CN110616192B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910732612.2A CN110616192B (zh) 2019-08-09 2019-08-09 一种抗人神经丝轻链(nefl)的单克隆抗体及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910732612.2A CN110616192B (zh) 2019-08-09 2019-08-09 一种抗人神经丝轻链(nefl)的单克隆抗体及其应用

Publications (2)

Publication Number Publication Date
CN110616192A CN110616192A (zh) 2019-12-27
CN110616192B true CN110616192B (zh) 2021-11-09

Family

ID=68921792

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910732612.2A Active CN110616192B (zh) 2019-08-09 2019-08-09 一种抗人神经丝轻链(nefl)的单克隆抗体及其应用

Country Status (1)

Country Link
CN (1) CN110616192B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112980861A (zh) * 2021-02-25 2021-06-18 安徽环球基因科技有限公司 一种人神经丝轻链的原核表达载体构建及蛋白的纯化方法
CN113817062B (zh) * 2021-07-26 2023-06-23 无锡傲锐东源生物科技有限公司 抗人羟基类固醇17-β脱氢酶13(HSD17B13)兔单克隆抗体及其应用
CN113956355B (zh) * 2021-07-26 2023-06-23 无锡傲锐东源生物科技有限公司 抗人脑利钠肽(bnp)兔单克隆抗体及其应用
CN116675768B (zh) * 2023-05-10 2024-02-27 武汉爱博泰克生物科技有限公司 针对人nefl蛋白的兔单克隆抗体及其制备方法和应用
CN117164711B (zh) * 2023-09-28 2024-01-30 北京凯祥弘康生物科技有限公司 一种抗神经纤维丝轻链蛋白的抗体
CN117069837B (zh) * 2023-09-28 2024-04-16 北京凯祥弘康生物科技有限公司 抗神经纤维丝轻链蛋白的特异性抗体和应用
CN117088976B (zh) * 2023-09-28 2024-03-08 北京凯祥弘康生物科技有限公司 一种抗nfl的单克隆抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011030329A1 (en) * 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
CN108048406A (zh) * 2017-12-27 2018-05-18 天津三箭生物技术股份有限公司 小鼠抗人Thyroglobulin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910100B2 (en) * 2004-10-01 2011-03-22 Max-Planck-Gesellschaft zur Forderung der Wissen Antibodies directed to the mammalian EAG1 ion channel protein
EP2933335A1 (en) * 2014-04-18 2015-10-21 Genethon A method of treating peripheral neuropathies and motor neuron diseases
US11697680B2 (en) * 2016-11-21 2023-07-11 Cureab Gmbh Anti-GP73 antibodies and immunoconjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011030329A1 (en) * 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
CN108048406A (zh) * 2017-12-27 2018-05-18 天津三箭生物技术股份有限公司 小鼠抗人Thyroglobulin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株

Also Published As

Publication number Publication date
CN110616192A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
CN110616192B (zh) 一种抗人神经丝轻链(nefl)的单克隆抗体及其应用
CN110684740B (zh) 一种抗人泛素羧基末端水解酶-1(uch-l1)的单克隆抗体及其应用
CN114181908B (zh) 抗人s100b蛋白鼠单克隆抗体及其应用
CN116693681B (zh) 抗幽门螺杆菌细胞毒素相关蛋白a的单克隆抗体及其应用
CN116355091A (zh) 一种抗人神经丝轻链的单克隆抗体21d2-30d3及其产品和应用
CN115724958B (zh) 抗诺如病毒gⅱ基因组衣壳蛋白vp1的单克隆抗体及其应用
CN106866820B (zh) 一种用于捕获肿瘤细胞的抗人角蛋白18的单克隆抗体及其应用
CN116375856A (zh) 一种抗Tau蛋白的单克隆抗体1A5-47H7和基于其的产品以及应用
CN114276445B (zh) 轮状病毒重组蛋白特异性抗体、质粒载体及方法
CN111705066B (zh) 一种经基因修饰的tigit蛋白及其单克隆抗体和应用
CN111378034B (zh) 抗恶性疟原虫hrp-ii抗体
WO2020253187A1 (zh) 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用
CN111763255B (zh) 一种经基因修饰的vegfa蛋白及其单克隆抗体与应用
CN107383200B (zh) 鼠源抗人IgE单克隆抗体的制备方法及其应用
CN111778257A (zh) 一种经基因修饰的cd96蛋白及其单克隆抗体和应用
CN114456265B (zh) 一种抗hfabp单克隆抗体及其应用
CN111378035B (zh) 抗恶性疟原虫hrp-ii重组抗体
CN116041525B (zh) Dcp特异性抗体及其应用
CN112250767B (zh) 一种结合Strep-Tag II标签的抗体及其应用
CN116987194B (zh) 人st2抗原的模拟表位肽的抗独特型纳米抗体及应用
CN113999306B (zh) 一种获得识别空间构象表位抗体的方法
CN114133447B (zh) 2019-nCoV表面蛋白受体结合区抗体制备方法及用途
JP6099393B2 (ja) オートタキシンアイソフォーム特異的抗体および検出方法
WO2024067151A1 (zh) 抗呼吸道合胞病毒抗体及其相关应用
EP4293360A1 (en) Adult still&#39;s disease inspection method and inspection kit

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant